董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Heiden | 男 | Director | 65 | 14.14万美元 | 1.52 | 2025-09-02 |
| Gregory A. Ciongoli | 男 | Director and Chair of the Board | 49 | 未披露 | 未持股 | 2025-09-02 |
| AnhCo Nguyen | 男 | President, Chief Executive Officer and Director | 52 | 106.81万美元 | 3.70 | 2025-09-02 |
| Matthew K. Fust | 男 | Director | 60 | 13.64万美元 | 1.12 | 2025-09-02 |
| Carol Gallagher | 女 | Lead Independent Director | 60 | 14.67万美元 | 2.60 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| AnhCo Nguyen | 男 | President, Chief Executive Officer and Director | 52 | 106.81万美元 | 3.70 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- William Heiden
-
William Heiden，自2015年11月起担任董事会成员。Heiden先生于2012年5月至2020年4月期间担任制药公司Amag制药，Inc.“AMAG”的总裁兼首席执行官和董事会成员。在加入AMAG之前，Heiden先生曾于2010年6月至2012年5月担任生物治疗公司GTC Biotherapeutics，Inc.（现为LFB，S.A.的一部分）的总裁兼首席执行官。2004年9月至2008年12月，Heiden先生担任生物制药公司Elixir Pharmaceuticals，Inc.（“Elixir”）的总裁兼首席执行官。在加入Elixir之前，Heiden先生曾于2002年至2004年担任Praecis Pharmaceuticals Incorporated（被葛兰素史克公司收购）的总裁兼首席运营官。从1987年到2002年，Heiden先生在Schering-Plough Corporation（已被默沙东公司收购）担任越来越重要的职务，包括管理美国、欧洲和加拿大的多项业务。Heiden先生拥有康奈尔大学约翰逊管理研究生院的工商管理硕士学位、鲁汶大学的M.I.M。学位和佛罗里达大学的学士学位。
William Heiden,has served as a member of the Board since November 2015. Mr. Heiden served as the President and Chief Executive Officer, and as a member of the board of directors, of AMAG Pharmaceuticals, Inc. (acquired by Covis Pharma GmbH), a pharmaceutical company, from May 2012 until April 2020. Prior to joining AMAG, Mr. Heiden served as President and Chief Executive Officer of GTC Biotherapeutics, Inc. (now part of LFB, S.A.), a biotherapeutics company, from June 2010 to May 2012. From September 2004 until December 2008, Mr. Heiden served as President and Chief Executive Officer of Elixir Pharmaceuticals, Inc., ("Elixir") a biopharmaceutical company. Prior to joining Elixir, Mr. Heiden served as President and Chief Operating Officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (which was acquired by Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden has served on the board of directors of Macrogenics, Inc. since May 2022. Mr. Heiden holds an M.B.A. from Cornell University's Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain, and a B.A. degree from the University of Florida. - William Heiden，自2015年11月起担任董事会成员。Heiden先生于2012年5月至2020年4月期间担任制药公司Amag制药，Inc.“AMAG”的总裁兼首席执行官和董事会成员。在加入AMAG之前，Heiden先生曾于2010年6月至2012年5月担任生物治疗公司GTC Biotherapeutics，Inc.（现为LFB，S.A.的一部分）的总裁兼首席执行官。2004年9月至2008年12月，Heiden先生担任生物制药公司Elixir Pharmaceuticals，Inc.（“Elixir”）的总裁兼首席执行官。在加入Elixir之前，Heiden先生曾于2002年至2004年担任Praecis Pharmaceuticals Incorporated（被葛兰素史克公司收购）的总裁兼首席运营官。从1987年到2002年，Heiden先生在Schering-Plough Corporation（已被默沙东公司收购）担任越来越重要的职务，包括管理美国、欧洲和加拿大的多项业务。Heiden先生拥有康奈尔大学约翰逊管理研究生院的工商管理硕士学位、鲁汶大学的M.I.M。学位和佛罗里达大学的学士学位。
- William Heiden,has served as a member of the Board since November 2015. Mr. Heiden served as the President and Chief Executive Officer, and as a member of the board of directors, of AMAG Pharmaceuticals, Inc. (acquired by Covis Pharma GmbH), a pharmaceutical company, from May 2012 until April 2020. Prior to joining AMAG, Mr. Heiden served as President and Chief Executive Officer of GTC Biotherapeutics, Inc. (now part of LFB, S.A.), a biotherapeutics company, from June 2010 to May 2012. From September 2004 until December 2008, Mr. Heiden served as President and Chief Executive Officer of Elixir Pharmaceuticals, Inc., ("Elixir") a biopharmaceutical company. Prior to joining Elixir, Mr. Heiden served as President and Chief Operating Officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (which was acquired by Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden has served on the board of directors of Macrogenics, Inc. since May 2022. Mr. Heiden holds an M.B.A. from Cornell University's Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain, and a B.A. degree from the University of Florida.
- Gregory A. Ciongoli
-
Gregory A. Ciongoli是美国公民。
Gregory A. Ciongoli has served as a member of Board of Directors since Augt 2025. Mr. Ciongoli is currently the Founder and Managing partner at Adiumentum Capital Management, a Boston based investment firm, and has served in that role since March 2024. Mr. Ciongoli has also served on the board of directors of Atara Biotherapeutics since September 2024, including as board chair since September 2025. Mr. Ciongoli served as a Public Group Investing Partner at the Baupost Group from 2007 to 2024. Mr. Ciongoli has served on the board of directors of Pelotero Corp. since March 2020, 33[rd] Team since September 2022, and Wavebreak Therapeutics since Augt 2017, and served as a board observer at Viasat Inc. from October 2018 to May 2023. In addition, Mr. Ciongoli previoly served as a board observer at Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Orexigen Therapeutics and Translate Bio. Earlier in his career, Mr. Ciongoli held the position of Director in the Event Driven Equity Group at Sowood Capital Management from 2005 to 2007 and worked as an Investment Analyst at Vinik Asset Management from 2003 to 2005 and at Thomas H. Lee Partners from 1999 to 2001. Mr. Ciongoli began his career as a Financial Analyst in the Healthcare Investment Banking Group at Goldman, Sachs & Co. from 1997 to 1999. Mr. Ciongoli also serves as the Chair of the Advisory Board for the James Madison Program in American Ideals and Institutions at Princeton University, and is actively involved in a number of local not for profit organizations. Mr. Ciongoli earned a Master in Biness Administration degree from Harvard Biness School in June 2003 and earned his Bachelor of Arts degree from the Woodrow Wilson School of Public and International Affairs at Princeton University in 1997. - Gregory A. Ciongoli是美国公民。
- Gregory A. Ciongoli has served as a member of Board of Directors since Augt 2025. Mr. Ciongoli is currently the Founder and Managing partner at Adiumentum Capital Management, a Boston based investment firm, and has served in that role since March 2024. Mr. Ciongoli has also served on the board of directors of Atara Biotherapeutics since September 2024, including as board chair since September 2025. Mr. Ciongoli served as a Public Group Investing Partner at the Baupost Group from 2007 to 2024. Mr. Ciongoli has served on the board of directors of Pelotero Corp. since March 2020, 33[rd] Team since September 2022, and Wavebreak Therapeutics since Augt 2017, and served as a board observer at Viasat Inc. from October 2018 to May 2023. In addition, Mr. Ciongoli previoly served as a board observer at Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Orexigen Therapeutics and Translate Bio. Earlier in his career, Mr. Ciongoli held the position of Director in the Event Driven Equity Group at Sowood Capital Management from 2005 to 2007 and worked as an Investment Analyst at Vinik Asset Management from 2003 to 2005 and at Thomas H. Lee Partners from 1999 to 2001. Mr. Ciongoli began his career as a Financial Analyst in the Healthcare Investment Banking Group at Goldman, Sachs & Co. from 1997 to 1999. Mr. Ciongoli also serves as the Chair of the Advisory Board for the James Madison Program in American Ideals and Institutions at Princeton University, and is actively involved in a number of local not for profit organizations. Mr. Ciongoli earned a Master in Biness Administration degree from Harvard Biness School in June 2003 and earned his Bachelor of Arts degree from the Woodrow Wilson School of Public and International Affairs at Princeton University in 1997.
- AnhCo Nguyen
-
AnhCo Nguyen，自2024年9月起担任总裁兼首席执行官和董事会成员。Nguyen博士于2021年5月加入公司，担任高级副总裁兼首席科学官，并于2023年5月担任执行副总裁兼首席科学技术官。在2021年5月加入公司之前，Nguyen博士曾在Fate Therapeutics, Inc.担任研发方面日益重要的职务，最近担任的是研发创新副总裁。此前，从2018年4月至2019年11月，Nguyen博士在辉瑞担任肿瘤研发高级总监。Nguyen博士在哈佛大学获得生物学本科学位，在圣路易斯华盛顿大学获得免疫学博士学位。他是麻省理工学院癌症研究中心的博士后研究员。
AnhCo Nguyen,has served as President and Chief Executive Officer and a member of the Board since September 2024. Dr. Nguyen joined the Company in May 2021 as Senior Vice President, Chief Scientific Officer and assumed the role of Executive Vice President, Chief Scientific and Technical Officer in May 2023. Prior to joining the Company in May 2021, Dr. Nguyen held roles of increasing responsibility in research and development at Fate Therapeutics, Inc., most recently as its Vice President, Research and Development Innovation. Previously, from April 2018 to November 2019, Dr. Nguyen served as Senior Director, Oncology R&D at Pfizer. Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology. - AnhCo Nguyen，自2024年9月起担任总裁兼首席执行官和董事会成员。Nguyen博士于2021年5月加入公司，担任高级副总裁兼首席科学官，并于2023年5月担任执行副总裁兼首席科学技术官。在2021年5月加入公司之前，Nguyen博士曾在Fate Therapeutics, Inc.担任研发方面日益重要的职务，最近担任的是研发创新副总裁。此前，从2018年4月至2019年11月，Nguyen博士在辉瑞担任肿瘤研发高级总监。Nguyen博士在哈佛大学获得生物学本科学位，在圣路易斯华盛顿大学获得免疫学博士学位。他是麻省理工学院癌症研究中心的博士后研究员。
- AnhCo Nguyen,has served as President and Chief Executive Officer and a member of the Board since September 2024. Dr. Nguyen joined the Company in May 2021 as Senior Vice President, Chief Scientific Officer and assumed the role of Executive Vice President, Chief Scientific and Technical Officer in May 2023. Prior to joining the Company in May 2021, Dr. Nguyen held roles of increasing responsibility in research and development at Fate Therapeutics, Inc., most recently as its Vice President, Research and Development Innovation. Previously, from April 2018 to November 2019, Dr. Nguyen served as Senior Director, Oncology R&D at Pfizer. Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology.
- Matthew K. Fust
-
Matthew K. Fust，自2014年3月起担任董事会成员。他是life sciences companies的董事会成员和顾问。Fust先生自2018年2月起担任Crinetics Pharmaceuticals， Inc.董事会成员，自2014年1月起担任Ultragenyx Pharmaceutical， Inc.董事会成员，自2020年12月起担任Neumora Therapeutics， Inc.董事会成员。Fust先生曾担任Sunesis Pharmaceuticals， Inc.（2005年至2017年），MacroGenics, Inc.（2014年3月至2020年5月任期届满）和Dermira， Inc.（2014年4月至2020年2月被礼来公司收购）的董事会成员。他曾担任Onyx Pharmaceuticals， Inc.（生物制药公司）的执行副总裁兼首席财务官（从2009年1月到2013年10月被Amgen收购）。他一直担任Amgen的员工，直到2014年1月。从2003年5月到2008年12月，他担任Jazz Pharmaceuticals， Inc.（一家专业制药公司）的首席财务官。2002年至2003年，他担任Perlegen Sciences（生物制药公司）的首席财务官。此前，他曾担任ALZA Corporation（制药公司）的高级副总裁兼首席财务官（从1996年到2002年）。从1991年到1996年，他是Andersen Consulting医疗保健战略实践的经理。他持有Minnesota大学的学士学位和the Stanford Graduate School of Business的工商管理硕士学位。
Matthew K. Fust,has served on board of directors since February 2018. He is currently a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 through its acquisition by Amgen Inc. in October 2013. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a genetics company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. Mr. Fust serves on the board of directors of the following publicly traded biopharmaceutical companies: as a member of the audit committee at Atara Biotherapeutics, Inc., as a member of the audit committee and the nominating and corporate governance committee at Ultragenyx Pharmaceutical, Inc., and as a member of the audit committee and the compensation committee at Neumora Therapeutics, Inc.. Mr. Fust previously served on the board of directors of MacroGenics, Inc., Dermira, Inc., and Sunesis Pharmaceuticals, Inc. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business. Mr. Fust's experience as a chief financial officer in the life sciences industry, his leadership and management experience, and his service as a director of other biopharmaceutical companies, contributed to board of directors' conclusion that he should serve as a director of company. - Matthew K. Fust，自2014年3月起担任董事会成员。他是life sciences companies的董事会成员和顾问。Fust先生自2018年2月起担任Crinetics Pharmaceuticals， Inc.董事会成员，自2014年1月起担任Ultragenyx Pharmaceutical， Inc.董事会成员，自2020年12月起担任Neumora Therapeutics， Inc.董事会成员。Fust先生曾担任Sunesis Pharmaceuticals， Inc.（2005年至2017年），MacroGenics, Inc.（2014年3月至2020年5月任期届满）和Dermira， Inc.（2014年4月至2020年2月被礼来公司收购）的董事会成员。他曾担任Onyx Pharmaceuticals， Inc.（生物制药公司）的执行副总裁兼首席财务官（从2009年1月到2013年10月被Amgen收购）。他一直担任Amgen的员工，直到2014年1月。从2003年5月到2008年12月，他担任Jazz Pharmaceuticals， Inc.（一家专业制药公司）的首席财务官。2002年至2003年，他担任Perlegen Sciences（生物制药公司）的首席财务官。此前，他曾担任ALZA Corporation（制药公司）的高级副总裁兼首席财务官（从1996年到2002年）。从1991年到1996年，他是Andersen Consulting医疗保健战略实践的经理。他持有Minnesota大学的学士学位和the Stanford Graduate School of Business的工商管理硕士学位。
- Matthew K. Fust,has served on board of directors since February 2018. He is currently a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 through its acquisition by Amgen Inc. in October 2013. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a genetics company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. Mr. Fust serves on the board of directors of the following publicly traded biopharmaceutical companies: as a member of the audit committee at Atara Biotherapeutics, Inc., as a member of the audit committee and the nominating and corporate governance committee at Ultragenyx Pharmaceutical, Inc., and as a member of the audit committee and the compensation committee at Neumora Therapeutics, Inc.. Mr. Fust previously served on the board of directors of MacroGenics, Inc., Dermira, Inc., and Sunesis Pharmaceuticals, Inc. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business. Mr. Fust's experience as a chief financial officer in the life sciences industry, his leadership and management experience, and his service as a director of other biopharmaceutical companies, contributed to board of directors' conclusion that he should serve as a director of company.
- Carol Gallagher
-
Carol Gallagher，自2013年1月起担任董事会成员，自2023年12月起担任董事会首席独立董事。从2014年10月到2023年12月，她担任New Enterprise Associates（一家风险投资公司）的合伙人和风险顾问。加入New Enterprise Associates之前，2013年10月至2014年9月，她担任Frazier Healthcare（一家风险投资公司）的风险合伙人。2008年至2011年，她担任生物制药公司Calistoga Pharmaceuticals的总裁兼首席执行官，当时该公司被Gilead收购。2007年至2008年，她担任Metastatix， Inc.（生物制药公司）的总裁兼首席执行官。在此之前，从1989年开始，她曾在制药公司Eli Lilly and Company、Amgen、Agouron Pharmaceuticals、Pfizer、Biogen Inc.、CancerVax, Inc.和Anadys Pharmaceuticals， Inc.担任各种职务。除了Atara Biotherapeutics， Inc.她于2022年11月加入PMV Pharmaceuticals， Inc.，担任董事。她还在几家私人公司的董事会任职。Gallagher博士此前曾在Mirati Therapeutics（2023年6月至2024年1月，公司被收购）、Turning Point Therapeutics（生物技术公司）（2019年7月至2022年8月，公司被收购）、Frazier Life Sciences Acquisition Corp（特殊目的收购公司）（2020年11月至2022年11月）、Certara Inc.（生物制药工具公司）（2021年6月至2022年4月）、Millendo Therapeutics, Inc.的董事会任职。从2012年9月到2021年6月，她是一家生物技术公司；从2018年10月到2021年2月，她是一家生物制药公司；从2017年11月到2021年4月，她是一家生物制药公司Metacrine， Inc.。她曾就读于Vanderbilt大学，持有Kentucky大学的学士学位和药学博士学位。
Carol Gallagher,has served as a member of the Board since January 2013 and as lead independent Director of the Board since December 2023. From October 2014 to December 2023, Dr. Gallagher served as a partner and then venture advisor with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly and Company, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Inc., CancerVax, Inc. and Anadys Pharmaceuticals, Inc. In addition to Atara Biotherapeutics, Inc. Board, Dr. Gallagher serves as a director at PMV Pharmaceuticals, Inc. which she joined in November 2022. She also serves on several private company boards. Dr. Gallagher previously served on the boards of directors at Mirati Therapeutics from June 2023 until January 2024 when the company was acquired, Turning Point Therapeutics, a biotechnology company, from July 2019 until August 2022 when the company was acquired, Frazier Life Sciences Acquisition Corp., a special purpose acquisition company, from November 2020 until November 2022, Certara Inc., a biopharmaceutical tools company, from June 2021 until April 2022, Millendo Therapeutics, Inc., a biotechnology company, from September 2012 until June 2021, Annexon Biosciences, a biopharmaceutical company, from October 2018 until February 2021, and Metacrine, Inc., a biopharmaceutical company, from November 2017 until April 2021. Dr. Gallagher attended Vanderbilt University and holds B.S. and Doctor of Pharmacy degrees from the University of Kentucky. - Carol Gallagher，自2013年1月起担任董事会成员，自2023年12月起担任董事会首席独立董事。从2014年10月到2023年12月，她担任New Enterprise Associates（一家风险投资公司）的合伙人和风险顾问。加入New Enterprise Associates之前，2013年10月至2014年9月，她担任Frazier Healthcare（一家风险投资公司）的风险合伙人。2008年至2011年，她担任生物制药公司Calistoga Pharmaceuticals的总裁兼首席执行官，当时该公司被Gilead收购。2007年至2008年，她担任Metastatix， Inc.（生物制药公司）的总裁兼首席执行官。在此之前，从1989年开始，她曾在制药公司Eli Lilly and Company、Amgen、Agouron Pharmaceuticals、Pfizer、Biogen Inc.、CancerVax, Inc.和Anadys Pharmaceuticals， Inc.担任各种职务。除了Atara Biotherapeutics， Inc.她于2022年11月加入PMV Pharmaceuticals， Inc.，担任董事。她还在几家私人公司的董事会任职。Gallagher博士此前曾在Mirati Therapeutics（2023年6月至2024年1月，公司被收购）、Turning Point Therapeutics（生物技术公司）（2019年7月至2022年8月，公司被收购）、Frazier Life Sciences Acquisition Corp（特殊目的收购公司）（2020年11月至2022年11月）、Certara Inc.（生物制药工具公司）（2021年6月至2022年4月）、Millendo Therapeutics, Inc.的董事会任职。从2012年9月到2021年6月，她是一家生物技术公司；从2018年10月到2021年2月，她是一家生物制药公司；从2017年11月到2021年4月，她是一家生物制药公司Metacrine， Inc.。她曾就读于Vanderbilt大学，持有Kentucky大学的学士学位和药学博士学位。
- Carol Gallagher,has served as a member of the Board since January 2013 and as lead independent Director of the Board since December 2023. From October 2014 to December 2023, Dr. Gallagher served as a partner and then venture advisor with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly and Company, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Inc., CancerVax, Inc. and Anadys Pharmaceuticals, Inc. In addition to Atara Biotherapeutics, Inc. Board, Dr. Gallagher serves as a director at PMV Pharmaceuticals, Inc. which she joined in November 2022. She also serves on several private company boards. Dr. Gallagher previously served on the boards of directors at Mirati Therapeutics from June 2023 until January 2024 when the company was acquired, Turning Point Therapeutics, a biotechnology company, from July 2019 until August 2022 when the company was acquired, Frazier Life Sciences Acquisition Corp., a special purpose acquisition company, from November 2020 until November 2022, Certara Inc., a biopharmaceutical tools company, from June 2021 until April 2022, Millendo Therapeutics, Inc., a biotechnology company, from September 2012 until June 2021, Annexon Biosciences, a biopharmaceutical company, from October 2018 until February 2021, and Metacrine, Inc., a biopharmaceutical company, from November 2017 until April 2021. Dr. Gallagher attended Vanderbilt University and holds B.S. and Doctor of Pharmacy degrees from the University of Kentucky.
高管简历
中英对照 | 中文 | 英文- AnhCo Nguyen
AnhCo Nguyen，自2024年9月起担任总裁兼首席执行官和董事会成员。Nguyen博士于2021年5月加入公司，担任高级副总裁兼首席科学官，并于2023年5月担任执行副总裁兼首席科学技术官。在2021年5月加入公司之前，Nguyen博士曾在Fate Therapeutics, Inc.担任研发方面日益重要的职务，最近担任的是研发创新副总裁。此前，从2018年4月至2019年11月，Nguyen博士在辉瑞担任肿瘤研发高级总监。Nguyen博士在哈佛大学获得生物学本科学位，在圣路易斯华盛顿大学获得免疫学博士学位。他是麻省理工学院癌症研究中心的博士后研究员。
AnhCo Nguyen,has served as President and Chief Executive Officer and a member of the Board since September 2024. Dr. Nguyen joined the Company in May 2021 as Senior Vice President, Chief Scientific Officer and assumed the role of Executive Vice President, Chief Scientific and Technical Officer in May 2023. Prior to joining the Company in May 2021, Dr. Nguyen held roles of increasing responsibility in research and development at Fate Therapeutics, Inc., most recently as its Vice President, Research and Development Innovation. Previously, from April 2018 to November 2019, Dr. Nguyen served as Senior Director, Oncology R&D at Pfizer. Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology.- AnhCo Nguyen，自2024年9月起担任总裁兼首席执行官和董事会成员。Nguyen博士于2021年5月加入公司，担任高级副总裁兼首席科学官，并于2023年5月担任执行副总裁兼首席科学技术官。在2021年5月加入公司之前，Nguyen博士曾在Fate Therapeutics, Inc.担任研发方面日益重要的职务，最近担任的是研发创新副总裁。此前，从2018年4月至2019年11月，Nguyen博士在辉瑞担任肿瘤研发高级总监。Nguyen博士在哈佛大学获得生物学本科学位，在圣路易斯华盛顿大学获得免疫学博士学位。他是麻省理工学院癌症研究中心的博士后研究员。
- AnhCo Nguyen,has served as President and Chief Executive Officer and a member of the Board since September 2024. Dr. Nguyen joined the Company in May 2021 as Senior Vice President, Chief Scientific Officer and assumed the role of Executive Vice President, Chief Scientific and Technical Officer in May 2023. Prior to joining the Company in May 2021, Dr. Nguyen held roles of increasing responsibility in research and development at Fate Therapeutics, Inc., most recently as its Vice President, Research and Development Innovation. Previously, from April 2018 to November 2019, Dr. Nguyen served as Senior Director, Oncology R&D at Pfizer. Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology.